A potential mechanism of action for bictegravir asa therapeutic for COVID-19 could be inhibition of the ORF3ainteraction with the host protein VPS39, which in turn wouldneutralize ORF3a’s ability to block fusion of endosome–lysosome compartments and promote degradation of viralcomponents in lysosomes. Here, VPS39 is linked to COVID-19.